Global Renal Disease Market Overview:
Renal disease is a condition in which the kidneys stop working and are not able to remove waste and extra water from the blood or keep body chemicals in balance. The renal disease damages the nephron, unable for the kidney to function to remove the waste product from the body. The disease can cause other severe problems such as hypertension, kidney failure, brain aneurysm, and chronic pain. Other symptoms include blood in urine, kidney stones, urinary tract or kidney infections, and back or side pain. It may develop over many years and lead to renal disease. It has become a massive public health issue. An increase in the incidence of diabetes, high blood pressure, and hypertension in patients are driving factors for the renal disease market.
|Unit||Value (USD Million)|
|Customization Scope||Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility|
Rising Government Support for the Quality Generic Medicines.
Market Growth Drivers:
Increased Incidence of Kidney Diseases, Huge Demand for Pharmacotherapy and Technological Advancements in Dialysis and Surgeries
Shortage in Availability of Kidneys for Transplants, Need For Continuous Improvement in Treatments Offering and Weak Health System and Lack of Infrastructure
Global Shortage of Donors, Lack of Awareness and Other Misconceptions about Renal Disease and Abuse of Over-The-Counter Medicines
Treatment Advancement Such As - Kidneys from Non-Human Mammals, Creating a Bioartificial Kidney as a Permanent Solution to Kidney Failure and Growing Awareness about Machine Learning and Artificial Intelligence Algorithms to Classify Patients into Homogenous Subclasses
Renal Disease Market is a fragmented market due to the presence of various players. The players are focusing on developing technological advancements and therapeutic advancement for the betterment of public health related to renal diseases. Further growing demand for awareness about machine learning and artificial intelligence will contribute to increasing the market presence. The companies are also planning strategic activities such as product launches, collaborations, mergers, and acquisitions to sustain in the market and maintain their competitive edge.
Some of the key players profiled in the report are AM-Pharma (Netherlands), Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Atlentis Therapeutics (Switzerland), Calyxo (United States), Chinook Therapeutics (Canada), CinCor (India), Early is Good (United States), Federation Bio (United States), Renalytix (United Kingdom), Frenova Renal Research (United States), Goldfinch Bio (Cambridge), Kibow Biotech (United States), Liminal BioSciences (Canada) and Renalytix (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like The Rogosin Institute (United States), Vera Therapeutics (United States), ProKidney (United States) and Osprey Medical (United States). Considering Market by Disease Type, the sub-segment i.e. Chronic Kidney Disease will boost the Renal Disease market. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Renal Disease market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Renal Disease market. Considering Market by Symptoms, the sub-segment i.e. Loss of Appetite. will boost the Renal Disease market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Renal Disease market.
Latest Market Insights:
On October 2022, Pfizer acquired Biohaven Pharmaceuticals, the maker of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults., and On November 2021, GSK announced positive Phase III efficacy and safety data for daprodustat in patients with anemia due to chronic kidney disease. The positive primary efficacy and safety results confirm the potential for daprodustat to be a new oral treatment for patients with anemia due to chronic kidney disease (CKD) in both non-dialysis and dialysis settings. Daprodustat was developed based on the unique Nobel Prize-winning science that demonstrated how cells sense and adapts to oxygen availability.
On January 2023, Renalytix launched a consortium focused on advancing biomarker-based tests for predicting responses to existing drugs used by chronic kidney disease (CKD) patients.
What Can be Explored with the Renal Disease Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Renal Disease Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Renal Disease
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Renal Disease market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Renal Disease market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.